# US 2020/0392076 A1 · Antiviral agents for drug-resistant influenza a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392076 A1
- Document ID: US20200392076A1
- Status: Published application
- Kind: A1
- Application number: 16/859,121
- Filed: 2020-04-27
- Published: 2020-12-17
- Earliest claimed: 2015-12-17
- Assignees: Thomas Jefferson University; Ramot at Tel-Aviv University Ltd.
- Applicants: Thomas Jefferson University; Ramot At Tel-Aviv University LTD.
- Inventors: Nir Ben-Tal; Roger S. Armen; Laurence C. Eisenlor; Jitendra Belani; Michael Miller; Inbar Fish; Ori Kalid
- Web page: https://patentgrep.com/patent/US20200392076A1

## CPC

- C07C 311/16: having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- A61K 31/04: Nitro compounds
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/63: Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61P 31/16: for influenza or rhinoviruses
- C07C 311/29: having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through adminstration of the same.

## Claims

### Claim 1

A compound of Formula 1:
wherein X1, X2, X3, X4, X6, X7, and X8 are independently a hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br; and
X5 is a CH2OH, hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1 selected from the group consisting of 4-[5-(hydroxymethyl)-2-methyl-7-oxabicyclo[3.3.1]non-2-en-8-yl]phenol, [8-(4-methoxyphenyl)-2,4,9-trimethyl-7-oxabicyclo[3.3.1]non-2-en-5-yl]methanol, 4-(2,2,6-trimethyl-3-oxabicyclo[3.3.1]non-6-en-4-yl)phenol, 4-[5-(hydroxymethyl)-2,4,9-trimethyl-7-oxabicyclo[3.3.1]non-2-en-8-yl]-2-methoxyphenol, N-benzyl-2,4,6-trimethylbenzenesulfonamide, 2,4,6-trimethyl-N-[(3-methylphenyl)methyl]benzenesulfonamide, N-[(2-chlorophenyl)methyl]-2,4,6 trimethylbenzenesulfonamide, 2,6-dimethyl-4-nitro-N-(pyridin-2-ylmethyl) benzenesulfonamide, and N-[(2-methoxyphenyl)methyl]-2,4,6 trimethylbenzenesulfonamide; 2-(1-adamantyl)-N-(4-nitrophenyl)acetamide, 3,5-dimethyl-N-(4-nitrophenyl)adamantane-1-carboxamide, 2-(1-adamantyl)-N-(2-methyl-4-nitrophenyl)acetamide, 3-(4-nitrophenyl)adamantan-1-ol, 1-(4-nitrophenyl)adamantane, or a pharmaceutically acceptable salt of any of these compounds.

### Claim 3

A compound of Formula 2:
wherein X1, X2, X4, X5, X6, X7, X8, X9, X10, X11, and X12 hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br; and
X3 is a nitro, nitrile, carboxyl, ester, sulfonamide, methylsulfone, hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
or a pharmaceutially acceptable salt thereof, with the proviso that X1 and X5 are not both methyl when X2, X4, X6, X7, X8, X9, X10, and X11 are hydrogen; X12 is a methoxy or Cl, and X3 is a nitro.

### Claim 4 (depends on 3)

A compound of claim 3 selected from the group consisting of N-benzyl-2,4,6-trimethylbenzenesulfonamide, 2,4,6-trimethyl-N-[(3-methylphenyl)methyl]benzenesulfonamide, N-[(2-chlorophenyl)methyl]-2,4,6 trimethylbenzenesulfonamide, 2,6-dimethyl-4-nitro-N-(pyridin-2-ylmethyl) benzenesulfonamide, and N-[(2-methoxyphenyl)methyl]-2,4,6 trimethylbenzenesulfonamide.

### Claim 5 (depends on 2)

A compound of claim 2 selected from the group consisting of 2-(1-adamantyl)-N-(4-nitrophenyl)acetamide, 3,5-dimethyl-N-(4-nitrophenyl)adamantane-1-carboxamide, 2-(1-adamantyl)-N-(2-methyl-4-nitrophenyl)acetamide, 3-(4-nitrophenyl)adamantan-1-ol, 1-(4-nitrophenyl)adamantane, or a pharmaceutically acceptable salt of any of these compounds.

### Claim at position 6

-14. (canceled)

### Claim 15 (depends on 1)

A method of treating amantadine-resistant influenza A infections comprising administering an effective amount of a compound of claim 1.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically-acceptable diluent or carrier.

### Claim 17 (depends on 16)

A method of treating amantadine-resistant influenza A infections comprising administering a pharmaceutical composition comprising of claim 16.

### Claim 18 (depends on 2)

A method of treating amantadine-resistant influenza A infections comprising administering an effective amount of a compound of claim 2.

### Claim 19 (depends on 2)

A pharmaceutical composition comprising an effective amount of a compound of claim 2 and a pharmaceutically-acceptable diluent or carrier.

### Claim 20 (depends on 19)

A method of treating amantadine-resistant influenza A infections comprising administering a pharmaceutical composition of claim 19.

### Claim 21 (depends on 5)

A method of treating amantadine-resistant influenza A infections comprising administering an effective amount of a compound of claim 5.

### Claim 22 (depends on 5)

A pharmaceutical composition comprising an effective amount of a compound of claim 5 and a pharmaceutically-acceptable diluent or carrier.

### Claim 23 (depends on 22)

A method of treating amantadine-resistant influenza A infections comprising administering a pharmaceutical composition of claim 22.

### Claim 24 (depends on 3)

A method of treating amantadine-resistant influenza A infections comprising administering an effective amount of a compound of claim 3.

### Claim 25 (depends on 3)

A pharmaceutical composition comprising an effective amount of a compound of claim 3 and a pharmaceutically-acceptable diluent or carrier.

### Claim 26 (depends on 25)

A method of treating amantadine-resistant influenza A infections comprising administering a pharmaceutical composition of claim 25.

### Claim 27 (depends on 4)

A method of treating amantadine-resistant influenza A infections comprising administering an effective amount of a compound of claim 4.

### Claim 28 (depends on 4)

A pharmaceutical composition comprising an effective amount of a compound of claim 4 and a pharmaceutically-acceptable diluent or carrier.

### Claim 29 (depends on 28)

A method of treating amantadine-resistant influenza A infections comprising administering a pharmaceutical composition of claim 28.
